Pietro Antenucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pietro Antenucci has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Andrea Gozzi
U.O. Neurologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy
6 shared publicationsJay Guido Capone
Unit of Neurology, Interdistrict Department of Neuroscience Sant'Anna University‐Hospital Ferrara Italy
4 shared publicationsMariachiara Sensi
U.O. Neurologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy
4 shared publicationsMarina Padroni
U.O. Neurologia, Stroke Unit, Azienda Ospedaliera Universitaria S. Anna, Ferrara 44124, Italy
4 shared publicationsMaura Pugliatti
Unit of Clinical Neurology, Interdistrict Department of Neuroscience and Rehabilitation University of Ferrara Ferrara Italy
4 shared publications- Anna Latorre
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, 33 Queen Square, London WC1N 3BG, UK
3 shared publications
Latest Publications
- 18 November 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (12)
Safety and quality of life outcome of trans-anal irrigation for chronic constipation in Parkinson’s disease: a pilot study
Constipation in Parkinson's Disease (PD) is the main and most disabling non-motor symptom. Laxatives, prebiotics and probiotics are therapeutic options for neurological bowel diseases, and recently, Trans-Anal Irrigation (TAI) has also been considered in poor responders to medical treatment. The primary aim was to evaluate safety and indication of TAI in treating PD constipation. A pilot, prospective, observational, cohort study enrolled PD patients with chronic constipation. At baseline, TAI was proposed. Patients who accepted TAI had a neurological and proctological assessment at baseline (T0), 6-month (T1) and 12-month (T2). Twelve patients accepted TAI. At T1 and T2, no side effects were recorded. TAI patients showed statistically improved proctological assessment (p < 0.001) and unchanged neurological scores except for the PDQ-39 questionnaire (p < 0.001) at T2. TAI is safe for constipation treatment in PD. Improving intestinal transit might ameliorate quality of life, laying the foundation for new therapeutic strategies.
- 18 November 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (12)
Safety and quality of life outcome of trans-anal irrigation for chronic constipation in Parkinson’s disease: a pilot study
Constipation in Parkinson's Disease (PD) is the main and most disabling non-motor symptom. Laxatives, prebiotics and probiotics are therapeutic options for neurological bowel diseases, and recently, Trans-Anal Irrigation (TAI) has also been considered in poor responders to medical treatment. The primary aim was to evaluate safety and indication of TAI in treating PD constipation. A pilot, prospective, observational, cohort study enrolled PD patients with chronic constipation. At baseline, TAI was proposed. Patients who accepted TAI had a neurological and proctological assessment at baseline (T0), 6-month (T1) and 12-month (T2). Twelve patients accepted TAI. At T1 and T2, no side effects were recorded. TAI patients showed statistically improved proctological assessment (p < 0.001) and unchanged neurological scores except for the PDQ-39 questionnaire (p < 0.001) at T2. TAI is safe for constipation treatment in PD. Improving intestinal transit might ameliorate quality of life, laying the foundation for new therapeutic strategies.
- Open Access
- 30 June 2026
- Published by Medical Communications Sp. z.o.o. in Journal of Ultrasonography
- Vol. 26 (105)
Ultrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study
Aim: Migraine is the second most disabling condition worldwide. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway represent an effective prophylactic treatment; however, their impact on cerebral hemodynamics remains unclear. The aim of this pilot study was to evaluate cerebrovas- cular risk in patients with migraine without aura treated with these therapies, by calculating the breath-holding index (BHI) of the anterior cerebral circulation using transcranial color-coded Doppler (TCCD) ultrasonography. Material and methods: Cerebral vasomotor reactivity to hypercapnia was assessed using the breath-holding test combined with TCCD ultrasonography in 40 patients with migraine without aura undergoing treatment with anti-CGRP monoclonal antibodies and 40 healthy subjects. BHI values and other key cerebrovascular parameters were compared between the groups. Results: The BHI values in patients with migraine without aura were not below the threshold predictive of increased cerebrovascular risk (less than 0.69% per second, as referenced in the general population). No significant differences were observed in major cerebrovascular parameters between cases and controls. Additionally, a subanalysis revealed no significant differences based on the specific monoclonal antibody (erenumab, fremanezumab, or galcanezumab) or clinical response status (responders versus non-responders). Conclusions: Our findings suggest that treatment with anti-CGRP monoclonal antibodies is not associated with a BHI indicative of increased cerebrovascular risk. Notably, this is the first study to include galcanezumab and fremanezumab in the evaluation of cerebrovascular risk using ultrasound, highlighting TCCD ultrasonography as a practical and non-invasive tool for the assessment of cerebrovascular reactivity in migraine.
- 30 June 2026
- Published by Medical Communications Sp. z.o.o. in Journal of Ultrasonography
- Vol. 26 (105)
Open AccessUltrasound assessment of cerebrovascular risk via breath-holding index in migraine patients treated with anti-CGRP monoclonal antibodies: a pilot study
Aim: Migraine is the second most disabling condition worldwide. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway represent an effective prophylactic treatment; however, their impact on cerebral hemodynamics remains unclear. The aim of this pilot study was to evaluate cerebrovas- cular risk in patients with migraine without aura treated with these therapies, by calculating the breath-holding index (BHI) of the anterior cerebral circulation using transcranial color-coded Doppler (TCCD) ultrasonography. Material and methods: Cerebral vasomotor reactivity to hypercapnia was assessed using the breath-holding test combined with TCCD ultrasonography in 40 patients with migraine without aura undergoing treatment with anti-CGRP monoclonal antibodies and 40 healthy subjects. BHI values and other key cerebrovascular parameters were compared between the groups. Results: The BHI values in patients with migraine without aura were not below the threshold predictive of increased cerebrovascular risk (less than 0.69% per second, as referenced in the general population). No significant differences were observed in major cerebrovascular parameters between cases and controls. Additionally, a subanalysis revealed no significant differences based on the specific monoclonal antibody (erenumab, fremanezumab, or galcanezumab) or clinical response status (responders versus non-responders). Conclusions: Our findings suggest that treatment with anti-CGRP monoclonal antibodies is not associated with a BHI indicative of increased cerebrovascular risk. Notably, this is the first study to include galcanezumab and fremanezumab in the evaluation of cerebrovascular risk using ultrasound, highlighting TCCD ultrasonography as a practical and non-invasive tool for the assessment of cerebrovascular reactivity in migraine.
- Open Access
- 25 May 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 268, 109513
Uninterrupted oral anticoagulation plus short-term single antiplatelet therapy in anticoagulated patients undergoing carotid artery stenting
- 25 May 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 268, 109513
Open AccessUninterrupted oral anticoagulation plus short-term single antiplatelet therapy in anticoagulated patients undergoing carotid artery stenting
- Open Access
- 17 April 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 187, 2111895
The Bereitschaftspotential in Voluntary Movement and Movement Disorders: Potential, Limitations and New Perspectives
- 17 April 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 187, 2111895
Open AccessThe Bereitschaftspotential in Voluntary Movement and Movement Disorders: Potential, Limitations and New Perspectives
- Open Access
- 16 March 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4)
Neurosarcoidosis-like reaction under TNF-α inhibitors: a case report and literature review of a paradoxical immune phenomenon
Background: Neurosarcoidosis (NS) is a rare manifestation of sarcoidosis that oftenrequires long-term immunosuppressive treatment (IST), including tumor necrosis factor-α (TNF-α) inhibitors in refractory cases. Paradoxically, TNF-α blockade has also been associated withsarcoidosis-like reactions (SLRs), granulomatous inflammatory conditions that mimic idiopathicsarcoidosis. Case presentation: We report a case of NS occurring in the context of a TNF-αinhibitor–associated SLR and review previously reported cases during TNF-α inhibitor therapy. Discussion: A 25- year-old man with HLA-B27–negative ankylosing spondylitis developed anacute central nervous system (CNS) inflammatory syndrome during prolonged adalimumabtherapy. The diagnosis was supported by inflammatory cerebrospinal fluid (CSF) findings,including an elevated CD4+/CD8+ ratio, histologically confirmed pulmonary SLR, and sustainedradiological and neurological remission after adalimumab withdrawal. A review of the literatureidentified only seven reported cases of NS during anti-TNF-α therapy across heterogeneousimmune-mediated inflammatory diseases. Clinical and neuroimaging features were variable,whereas CSF analysis consistently showed inflammatory changes. Exposure duration prior toneurological onset and follow-up strategies were inconsistently reported, and acute IST wasfrequently required because of CNS involvement. Conclusions: This case expands the clinicalspectrum of anti-TNF-α– associated SLRs and underscores the importance of considering aniatrogenic etiology in paradoxical neuroinflammatory presentations. Recognition of a“neurosarcoidosis-like reaction” may inform long-term therapeutic decisions, including carefulconsideration of TNF-α inhibitor re-exposure and selection of alternative ISTs for the underlyingdisease.
- 16 March 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4)
Open AccessNeurosarcoidosis-like reaction under TNF-α inhibitors: a case report and literature review of a paradoxical immune phenomenon
Background: Neurosarcoidosis (NS) is a rare manifestation of sarcoidosis that oftenrequires long-term immunosuppressive treatment (IST), including tumor necrosis factor-α (TNF-α) inhibitors in refractory cases. Paradoxically, TNF-α blockade has also been associated withsarcoidosis-like reactions (SLRs), granulomatous inflammatory conditions that mimic idiopathicsarcoidosis. Case presentation: We report a case of NS occurring in the context of a TNF-αinhibitor–associated SLR and review previously reported cases during TNF-α inhibitor therapy. Discussion: A 25- year-old man with HLA-B27–negative ankylosing spondylitis developed anacute central nervous system (CNS) inflammatory syndrome during prolonged adalimumabtherapy. The diagnosis was supported by inflammatory cerebrospinal fluid (CSF) findings,including an elevated CD4+/CD8+ ratio, histologically confirmed pulmonary SLR, and sustainedradiological and neurological remission after adalimumab withdrawal. A review of the literatureidentified only seven reported cases of NS during anti-TNF-α therapy across heterogeneousimmune-mediated inflammatory diseases. Clinical and neuroimaging features were variable,whereas CSF analysis consistently showed inflammatory changes. Exposure duration prior toneurological onset and follow-up strategies were inconsistently reported, and acute IST wasfrequently required because of CNS involvement. Conclusions: This case expands the clinicalspectrum of anti-TNF-α– associated SLRs and underscores the importance of considering aniatrogenic etiology in paradoxical neuroinflammatory presentations. Recognition of a“neurosarcoidosis-like reaction” may inform long-term therapeutic decisions, including carefulconsideration of TNF-α inhibitor re-exposure and selection of alternative ISTs for the underlyingdisease.
- Open Access
- 13 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1918-1925
Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease
Background: Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives: To identify key factors to improve decision‐making in DBS management for LSPD patients. Methods: We retrospectively analyzed demographic, clinical and stimulation parameters in LSPD patients (Hoehn and Yahr ≥4; Schwab and England ≤50) who either maintained best medical therapy (BMT) or required unscheduled device‐aided therapy (DAT) implantation up to 1 year after DBS discontinuation. Results: From 2005 to 2022, 94 patients with bilateral subthalamic nucleus DBS were reviewed and among the 31 patients who have transitioned to LSPD, 15 patients remained on BMT, while 10 required rescue DAT (6 unscheduled implantable pulse generator replacements and 4 Levodopa‐Carbidopa Intestinal Gel) within 3 months after discontinuation. Significant differences were observed in years of DBS (12.4 vs. 8.5), modified Falls Efficacy Scale (12.5 vs. 21.2), and months since the last parameter adjustment (30.3 vs. 23.2), with a trend toward less ΔMDS‐UPDRS III worsening after stimulation was switched off (7.6 vs. 10.9). Longer DBS duration was inversely associated with rescue DAT (OR 0.529; 95% CI, 0.284–0.986), with a cutoff of 10.5 years. Conclusion: In selected LSPD patients, a transition from DBS to BMT alone can be attempted with long‐term stability, whereas in others a more conservative approach is advisable, and stimulation should be continued. Clinical, therapeutic, and care‐related factors should guide decisions when discontinuation is being considered.
- 13 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1918-1925
Open AccessRisk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease
Background: Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives: To identify key factors to improve decision‐making in DBS management for LSPD patients. Methods: We retrospectively analyzed demographic, clinical and stimulation parameters in LSPD patients (Hoehn and Yahr ≥4; Schwab and England ≤50) who either maintained best medical therapy (BMT) or required unscheduled device‐aided therapy (DAT) implantation up to 1 year after DBS discontinuation. Results: From 2005 to 2022, 94 patients with bilateral subthalamic nucleus DBS were reviewed and among the 31 patients who have transitioned to LSPD, 15 patients remained on BMT, while 10 required rescue DAT (6 unscheduled implantable pulse generator replacements and 4 Levodopa‐Carbidopa Intestinal Gel) within 3 months after discontinuation. Significant differences were observed in years of DBS (12.4 vs. 8.5), modified Falls Efficacy Scale (12.5 vs. 21.2), and months since the last parameter adjustment (30.3 vs. 23.2), with a trend toward less ΔMDS‐UPDRS III worsening after stimulation was switched off (7.6 vs. 10.9). Longer DBS duration was inversely associated with rescue DAT (OR 0.529; 95% CI, 0.284–0.986), with a cutoff of 10.5 years. Conclusion: In selected LSPD patients, a transition from DBS to BMT alone can be attempted with long‐term stability, whereas in others a more conservative approach is advisable, and stimulation should be continued. Clinical, therapeutic, and care‐related factors should guide decisions when discontinuation is being considered.
- 6 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1823-1833
Unraveling Peripheral Neuropathy in Parkinsonism from Acquired to Genetic Forms: A Review with Diagnostic Framework for Clinicians
Background: The coexistence of parkinsonism and peripheral neuropathy (PN) is more frequent than traditionally assumed and impacts patients’ quality of life. Despite this, PN is often overlooked or misattributed to non‐motor symptoms of Parkinson's disease (PD), resulting in missed diagnoses in clinical practice. Objectives: This review aims to summarize current evidence on the etiologies linking parkinsonism and PN and provide a diagnostic algorithm to support clinical decision‐making. Methods: Narrative review of studies on parkinsonism and PN, limited to 2000–2025 to capture recent advances. Results: Several factors have been proposed to explain the connection between parkinsonism and PN. Long‐term levodopa treatment has been associated with PN, due to metabolic disturbances, including vitamin B12 depletion and increased homocysteine levels. Small fiber neuropathy is commonly observed in PD and may precede motor symptom onset. Certain pathogenic variants, known to cause parkinsonian syndromes, have also been linked to peripheral nerve involvement ( PRKN , DJ1 , PINK1 , GBA , and ATP13A2 ), while some inherited neuropathies ( FIG4 , LRSAM1 , SLC25A46 , DNAJB2 , and AARS ) are characterized by overlapping parkinsonian features. Moreover, a wide range of acquired conditions expands the differential diagnosis. This growing body of evidence highlights the emerging role of peripheral nervous system involvement in parkinsonism and underscores the importance of its systematic assessment. Conclusions: PN is a relevant yet underrecognized comorbidity in patients with parkinsonism. Early identification is crucial for enhancing diagnostic accuracy and therapeutic outcomes. The diagnostic algorithm proposed offers a structured approach for clinicians, facilitating comprehensive evaluation and personalized management in this complex clinical context.
- 6 January 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1823-1833
Unraveling Peripheral Neuropathy in Parkinsonism from Acquired to Genetic Forms: A Review with Diagnostic Framework for Clinicians
Background: The coexistence of parkinsonism and peripheral neuropathy (PN) is more frequent than traditionally assumed and impacts patients’ quality of life. Despite this, PN is often overlooked or misattributed to non‐motor symptoms of Parkinson's disease (PD), resulting in missed diagnoses in clinical practice. Objectives: This review aims to summarize current evidence on the etiologies linking parkinsonism and PN and provide a diagnostic algorithm to support clinical decision‐making. Methods: Narrative review of studies on parkinsonism and PN, limited to 2000–2025 to capture recent advances. Results: Several factors have been proposed to explain the connection between parkinsonism and PN. Long‐term levodopa treatment has been associated with PN, due to metabolic disturbances, including vitamin B12 depletion and increased homocysteine levels. Small fiber neuropathy is commonly observed in PD and may precede motor symptom onset. Certain pathogenic variants, known to cause parkinsonian syndromes, have also been linked to peripheral nerve involvement ( PRKN , DJ1 , PINK1 , GBA , and ATP13A2 ), while some inherited neuropathies ( FIG4 , LRSAM1 , SLC25A46 , DNAJB2 , and AARS ) are characterized by overlapping parkinsonian features. Moreover, a wide range of acquired conditions expands the differential diagnosis. This growing body of evidence highlights the emerging role of peripheral nervous system involvement in parkinsonism and underscores the importance of its systematic assessment. Conclusions: PN is a relevant yet underrecognized comorbidity in patients with parkinsonism. Early identification is crucial for enhancing diagnostic accuracy and therapeutic outcomes. The diagnostic algorithm proposed offers a structured approach for clinicians, facilitating comprehensive evaluation and personalized management in this complex clinical context.
- 14 December 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 183, 2111479
Corticospinal excitability as distinctive neurophysiological feature of acquired glycine receptor antibody syndrome
- 14 December 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 183, 2111479
Corticospinal excitability as distinctive neurophysiological feature of acquired glycine receptor antibody syndrome
- 21 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1277-1282
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies
Background: Continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI) and intrajejunal levodopa‐carbidopa intestinal gel (LCIG) are established options for advanced Parkinson's disease (PD). Real‐world data on early titration and management are limited. Objectives: To compare clinical course, safety, and practical implications of titration with CSFLI versus LCIG. Methods: In this retrospective study across nine Italian centers using uniform titration protocols, we analyzed 103 patients treated with CSFLI and 129 with LCIG. Clinical outcomes, levodopa equivalent daily dose (LEDD), follow‐up needs, and adverse events were evaluated over 3 months. Results: Both therapies improved motor symptoms and quality of life. CSFLI required more frequent follow‐up visits and larger LEDD increases to reach optimization, with common but generally mild local reactions. LCIG showed fewer titration demands, with occasional peristomal issues. Conclusions: While equally effective, CSFLI requires closer supervision during early management. Recognizing these practical differences can guide therapy selection and service planning in advanced PD.
- 21 November 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (5) , 1277-1282
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies
Background: Continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI) and intrajejunal levodopa‐carbidopa intestinal gel (LCIG) are established options for advanced Parkinson's disease (PD). Real‐world data on early titration and management are limited. Objectives: To compare clinical course, safety, and practical implications of titration with CSFLI versus LCIG. Methods: In this retrospective study across nine Italian centers using uniform titration protocols, we analyzed 103 patients treated with CSFLI and 129 with LCIG. Clinical outcomes, levodopa equivalent daily dose (LEDD), follow‐up needs, and adverse events were evaluated over 3 months. Results: Both therapies improved motor symptoms and quality of life. CSFLI required more frequent follow‐up visits and larger LEDD increases to reach optimization, with common but generally mild local reactions. LCIG showed fewer titration demands, with occasional peristomal issues. Conclusions: While equally effective, CSFLI requires closer supervision during early management. Recognizing these practical differences can guide therapy selection and service planning in advanced PD.
- 15 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (2) , 410-418
Circadian Rhythms of Sleep–Wake, Thermoregulatory and Cardiovascular Function in Progressive Supranuclear Palsy
Background: The sleep–wake cycle and the autonomic nervous system (ANS) can be impaired in neurodegenerative diseases. Objectives: To describe sleep–wake cycle and circadian rhythms of body core temperature (BcT) and cardiovascular parameters in Progressive Supranuclear Palsy (PSP). Methods: We prospectively recorded 48 hour video‐polysomnography, BcT and blood pressure (BP) in 14 PSP patients (disease duration 5.9 ± 2.6 years) under controlled environmental conditions. We analyzed wake–sleep parameters and state‐dependent modulation for BcT, BP and heart rate from the last 24 h of recording. Twelve healthy younger controls were used for comparison. Results: Patients slept less than 5 hours/night with frequent awakenings, daytime naps were shorter than 60 minutes and mainly represented by light sleep resulting in a 24 h sleep deprivation. Patients with PSP slept less compared to younger controls and normative values for age. Only two patients reported excessive daytime sleepiness. There were no significant differences in sleep parameters according to the presence of sleep disorders. Compared to controls, patients showed significantly higher BcT values during wake and sleep. Twelve patients presented an abnormal BP pattern at nighttime. Conclusion: PSP patients experienced profound sleep deprivation across the 24 h study period. An imbalance between sympathetic and parasympathetic function with sympathetic predominance may be associated with this alteration. Whether this autonomic dysfunction is the primary drive for the sleep–wake cycle disruption or the consequence of sleep loss needs to be elucidated.
- 15 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (2) , 410-418
Circadian Rhythms of Sleep–Wake, Thermoregulatory and Cardiovascular Function in Progressive Supranuclear Palsy
Background: The sleep–wake cycle and the autonomic nervous system (ANS) can be impaired in neurodegenerative diseases. Objectives: To describe sleep–wake cycle and circadian rhythms of body core temperature (BcT) and cardiovascular parameters in Progressive Supranuclear Palsy (PSP). Methods: We prospectively recorded 48 hour video‐polysomnography, BcT and blood pressure (BP) in 14 PSP patients (disease duration 5.9 ± 2.6 years) under controlled environmental conditions. We analyzed wake–sleep parameters and state‐dependent modulation for BcT, BP and heart rate from the last 24 h of recording. Twelve healthy younger controls were used for comparison. Results: Patients slept less than 5 hours/night with frequent awakenings, daytime naps were shorter than 60 minutes and mainly represented by light sleep resulting in a 24 h sleep deprivation. Patients with PSP slept less compared to younger controls and normative values for age. Only two patients reported excessive daytime sleepiness. There were no significant differences in sleep parameters according to the presence of sleep disorders. Compared to controls, patients showed significantly higher BcT values during wake and sleep. Twelve patients presented an abnormal BP pattern at nighttime. Conclusion: PSP patients experienced profound sleep deprivation across the 24 h study period. An imbalance between sympathetic and parasympathetic function with sympathetic predominance may be associated with this alteration. Whether this autonomic dysfunction is the primary drive for the sleep–wake cycle disruption or the consequence of sleep loss needs to be elucidated.